registHER: An Observational Cohort Study of Patients With HER2 Positive Metastatic Breast Cancer

Genentech, Inc.0 sites1,000 target enrollmentMarch 2003

ConditionsBreast Cancer

Overview

Phase: N/A
Intervention: Not specified
Conditions: Breast Cancer
Sponsor: Genentech, Inc.
Enrollment: 1000
Status: Completed
Last Updated: 16 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

This is a prospective observational cohort study designed to describe effectiveness and safety (treatment outcomes and clinically significant cardiac adverse events, respectively) in patients with HER2-positive metastatic breast cancer.

Registry

clinicaltrials.gov

Start Date

March 2003

End Date

May 2009

Last Updated

16 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Genentech, Inc.

Eligibility Criteria

Inclusion Criteria

•Signed Informed Consent document (unless the IRB has granted a waiver of consent)
•Signed Authorization for the Use and Disclosure of Health Information document
•HER2-positive breast cancer
•Initial diagnosis of metastatic (Stage IV) breast cancer within 6 months prior to enrollment
•Availability of cancer-specific historical data points in the patient's medical records